跳至主要内容
临床试验/NCT00282113
NCT00282113已完成不适用

Efficacy of a Prebiotic and Probiotic Combination in Preterm Infants

University of California, Davis2 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2004年10月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
90
试验地点
2
主要终点
Weight Gain

研究概览

简要总结

The purpose of this study is to see how oral preparations containing both probiotics and prebiotics impact the growth, bacterial colonization of the intestines, and fecal short chain fatty acid content in premature infants. Our hypothesis is that short term growth will be improved, the stool will have more healthy bacteria, and the fecal short chain fatty acid content will increase in the babies who receive the probiotic/prebiotic combinations compared to control groups.

详细描述

Premature infants are at risk for a devastating infection of the intestines due to the immaturity of their intestines and immune system. Probiotics are bacteria with healthful qualities that are taken by mouth to improve the number of healthy bacteria in the intestines. Probiotics have been shown in several studies outside the U.S. to decrease the risk of serious intestinal infection and in one small study to improve the rate of weight gain in premature infants. Prebiotics are food supplements that stimulate the growth of healthy bacteria and suppress the growth of unhealthy bacteria. Prebiotics have been shown to improve the numbers of healthy bacteria in the stool of premature babies. Our study is designed to compare two over the counter probiotic/prebiotic combinations to each other and to a control group. Infants less than 35 weeks with a birthweight of 750-2000 gm are eligible and must be enrolled in the study within the first week of life. The babies are randomly assigned to either a control group (no probiotic/prebiotic, just a placebo), a group which receives Culturelle (Lactobacillus rhamnosus GG plus fructo-oligosaccharide, ConAgra), or a group which receives ProBioPlus (three strains of Bifidobacteria plus Lactobacillus acidophilus plus fructo-oligosaccharide, UAS Laboratories). The babies receive the study product by mouth twice daily for 28 days or until discharge (whichever comes first). Weekly measurements (weight, length, head size) and stool cultures are performed. Clinical progress is closely monitored and any episodes of infection are recorded.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Triple (Participant, Care Provider, Investigator)

入排标准

年龄范围
— 至 7 Days(Child)
性别
All
接受健康志愿者

入选标准

  • less than 35 weeks gestation, birth weight 750-2000 grams
  • born in or transferred to University of California Davis Medical Center within first week of life
  • less than eight days of age at the time of enrollment

排除标准

  • Severe intestinal or cardiac congenital anomalies

结局指标

主要结局

Weight Gain

时间窗: 5 weeks

Weight at five weeks minus birth weight

次要结局

  • Stool Colonization With Bifidobacteria(4 weeks)
  • Stool Short Chain Butyric Acid Content(4 weeks)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验